Skip to content

US · SLDB · BIOTECHNOLOGY

Solid Biosciences Inc. (SLDB) intrinsic value and stock valuation

$6.25as of 2026-11-21 · Mkt cap 825.99M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Solid Biosciences Inc. DCF and intrinsic value

InvestorsCraft values SLDB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SLDB’s statements →

Solid Biosciences Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Charlestown, MA 02139 solidbio.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-174.32M
20152025
Free cash flow
-$-157.44M
20152025
Total equity
$180M+6.4% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$8.09M$13.6M
Operating income-$-179.21M-$-129.73M-$-104.31M-$-106.45M-$-72.25M
Net income-$-174.32M-$-124.7M-$-96.02M-$-85.98M-$-72.19M
EPSd-$-1.99M-$-3.05M-$-4.83M-$-10.1M-$-10.14M
Operating cash flow-$-156.29M-$-100.01M-$-94.18M-$-97.98M-$-77.76M
Capital expenditure-$-1.15M-$-650K-$-1.51M-$-3.02M-$-1.28M
Free cash flow-$-157.44M-$-100.67M-$-95.69M-$-100.99M-$-79.05M
Total assets$232.5M$188.7M$164.9M$260.3M$232.4M
Total debt$21.2M$24.2M$26.3M$28.6M$2.06M
Net debt-$-38.74M-$-56.06M-$-47.75M-$-126.84M-$-117.07M
Total equity$180M$137.3M$126.5M$211.7M$208.2M
Cash and short-term investments$187.9M$148.9M$123.6M$213.7M$207.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$8.09M$13.6M
Cost of revenue$1.64M$2.46M$2.58M$0.00$0.00
Gross profit-$-1.64M-$-2.46M-$-2.58M$8.09M$13.6M
Research and development expenses$140.3M$96.4M$76.6M$78.4M$58.7M
Selling, general and administrative expenses$38.9M$33.3M$27.8M$29M$27.1M
Other expenses-$-1.64M-$-2.46M-$-2.58M$7.18M$0.00
Operating expenses$177.6M$127.3M$101.7M$114.6M$85.9M
Cost and expenses$179.2M$129.7M$104.3M$114.6M$85.9M
Interest income$9.9M$9.47M$7.14M$2.62M$60K
Interest expense$0.00$340K$0.00$0.00$0.00
Depreciation and amortization$1.64M$2.46M$2.58M$2.41M$2.96M
Ebitda-$-172.69M-$-121.9M-$-93.43M-$-96.87M-$-69.22M
Operating income-$-179.21M-$-129.73M-$-104.31M-$-106.45M-$-72.25M
Total other income/expenses, net$4.88M$5.03M$8.3M$20.5M$70K
Income before tax-$-174.32M-$-124.7M-$-96.02M-$-85.98M-$-72.19M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-174.32M-$-124.7M-$-96.02M-$-85.98M-$-72.19M
Weighted average shares outstanding$87.5M$40.8M$19.9M$8.51M$7.12M
Weighted average diluted shares outstanding$87.5M$40.8M$19.9M$8.51M$7.12M
Balance sheet
20252024202320222021
Cash and short-term investments$187.9M$148.9M$123.6M$213.7M$207.8M
Net receivables$0.00$0.00$0.00$0.00$110K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$205.5M$157.3M$129.7M$219.6M$222.6M
Property, plant and equipment, net$26.1M$29M$33.2M$38.6M$7.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$27.1M$31.4M$35.2M$40.6M$9.77M
Total assets$232.5M$188.7M$164.9M$260.3M$232.4M
Accounts payable$3.22M$4.24M$2.03M$3.24M$4.46M
Short-term debt$2.1M$3.02M$2.32M$2.56M$1.5M
Deferred revenue$0.00$0.00$0.00$0.00$8.08M
Total current liabilities$33.5M$30.3M$14.5M$22.5M$23.6M
Long-term debt$19.1M$21.2M$23.9M$26M$570K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$19.1M$21.2M$23.9M$26.1M$570K
Capital lease obligations$21.2M$24.2M$26.3M$28.6M$2.06M
Total liabilities$52.5M$51.4M$38.5M$48.6M$24.2M
Common stock$80K$40K$20K$20K$10K
Retained earnings-$-957.77M-$-783.45M-$-658.75M-$-562.74M-$-476.76M
Accumulated other comprehensive income (loss)$50K$50K$10K-$-70K-$-40K
Total equity$180M$137.3M$126.5M$211.7M$208.2M
Total investments$128M$68.7M$49.6M$58.3M$88.6M
Total debt$21.2M$24.2M$26.3M$28.6M$2.06M
Net debt-$-38.74M-$-56.06M-$-47.75M-$-126.84M-$-117.07M
Cash flow statement
20252024202320222021
Net income-$-174.32M-$-124.7M-$-96.02M-$-85.98M-$-72.19M
Depreciation and amortization-$-1.87M$2.46M$2.58M$2.41M$2.96M
Stock-based compensation$16.9M$10.5M$7.62M$7.54M$13.4M
Change in working capital-$-6.82M$2.85M-$-6.34M-$-3.69M-$-23.04M
Accounts receivable$0.00$0.00$0.00$110K-$-110K
Inventory$0.00$0.00$0.00$0.00-$-11.5M
Accounts payable-$-1.09M$2.21M-$-760K-$-5.25M$1.21M
Net cash provided by operating activities-$-156.29M-$-100.01M-$-94.18M-$-97.98M-$-77.76M
Investments in property, plant and equipment-$-1.15M-$-650K-$-1.51M-$-3.02M-$-1.28M
Acquisitions, net$90K$10K$0.00$31.5M$89.8M
Net cash used for investing activities-$-58.45M-$-16.09M$9.69M$59.2M-$-91.09M
Common stock issued$194.7M$127.2M$2.97M$72.6M$134.9M
Common stock repurchased$0.00-$-5.11M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$194.5M$122.4M$3.12M$74.8M$135M
Net change in cash-$-20.3M$6.34M-$-81.37M$36M-$-33.87M
Cash at end of period$61.9M$82.2M$74M$157.2M$121.2M
Operating cash flow-$-156.29M-$-100.01M-$-94.18M-$-97.98M-$-77.76M
Capital expenditure-$-1.15M-$-650K-$-1.51M-$-3.02M-$-1.28M
Free cash flow-$-157.44M-$-100.67M-$-95.69M-$-100.99M-$-79.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Solid Biosciences Inc.

        Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

        CEO
        Alexander G. Cumbo
        Employees
        121
        Beta
        2.36

        Explore

        Frequently asked questions

        What is the intrinsic value of Solid Biosciences Inc. (SLDB)?

        InvestorsCraft does not currently publish an intrinsic value for SLDB. How the IC value is calculated.

        Is SLDB undervalued?

        InvestorsCraft does not publish an undervaluation signal for SLDB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.